- Cancer drugmaker
- Incyte's stock was down as much as 22% before markets opened on Friday morning, while Merck's was down a little more than 1%.
- Cancer immunotherapy works by harnessing the body's immune system to treat cancer.
- The trial was looking to see if combining two drugs — Merck's PD1 checkpoint inhibitor and Incyte's IDO1 inhibitor — that both essentially take the brake off the immune system to go after the cancer cells in people with metastatic melanoma could work even better than Merck's drug alone.
ADVERTISEMENT
A cancer drugmaker just failed a key trial and its stock is crashing (INCY, MRK)
Cancer drugmaker Incyte said on Friday that a key trial combining its cancer immunotherapy drug with a blockbuster drug from Merck failed in a late-stage trial.
JOIN OUR PULSE COMMUNITY!
ADVERTISEMENT
Eyewitness? Submit your stories now via social or:
Email: eyewitness@pulse.ng
ADVERTISEMENT